1. Home
  2. STTK vs TCMD Comparison

STTK vs TCMD Comparison

Compare STTK & TCMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$6.18

Market Cap

275.9M

Sector

Health Care

ML Signal

HOLD

Logo Tactile Systems Technology Inc.

TCMD

Tactile Systems Technology Inc.

HOLD

Current Price

$25.73

Market Cap

300.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STTK
TCMD
Founded
2016
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
275.9M
300.1M
IPO Year
2020
2016

Fundamental Metrics

Financial Performance
Metric
STTK
TCMD
Price
$6.18
$25.73
Analyst Decision
Buy
Strong Buy
Analyst Count
7
4
Target Price
$7.60
$36.00
AVG Volume (30 Days)
617.5K
302.6K
Earning Date
03-05-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
53.02
17.14
EPS
N/A
0.82
Revenue
$1,000,000.00
N/A
Revenue This Year
N/A
$11.60
Revenue Next Year
N/A
$9.14
P/E Ratio
N/A
$33.01
Revenue Growth
N/A
N/A
52 Week Low
$0.69
$8.61
52 Week High
$6.27
$37.77

Technical Indicators

Market Signals
Indicator
STTK
TCMD
Relative Strength Index (RSI) 73.59 35.16
Support Level $1.85 $24.54
Resistance Level N/A $26.57
Average True Range (ATR) 0.42 1.12
MACD 0.05 -0.28
Stochastic Oscillator 93.80 4.63

Price Performance

Historical Comparison
STTK
TCMD

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About TCMD Tactile Systems Technology Inc.

Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.

Share on Social Networks: